Knetki-Wróblewska, M.; Tabor, S.; Płużański, A.; Lewandowska, Z.; Tysarowski, A.; Pawlik, H.; Kowalski, D.M.; Krzakowski, M.
Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice. Curr. Oncol. 2023, 30, 462-475.
https://doi.org/10.3390/curroncol30010037
AMA Style
Knetki-Wróblewska M, Tabor S, Płużański A, Lewandowska Z, Tysarowski A, Pawlik H, Kowalski DM, Krzakowski M.
Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice. Current Oncology. 2023; 30(1):462-475.
https://doi.org/10.3390/curroncol30010037
Chicago/Turabian Style
Knetki-Wróblewska, Magdalena, Sylwia Tabor, Adam Płużański, Zofia Lewandowska, Andrzej Tysarowski, Hubert Pawlik, Dariusz M. Kowalski, and Maciej Krzakowski.
2023. "Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice" Current Oncology 30, no. 1: 462-475.
https://doi.org/10.3390/curroncol30010037
APA Style
Knetki-Wróblewska, M., Tabor, S., Płużański, A., Lewandowska, Z., Tysarowski, A., Pawlik, H., Kowalski, D. M., & Krzakowski, M.
(2023). Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice. Current Oncology, 30(1), 462-475.
https://doi.org/10.3390/curroncol30010037
